Cited 42 times in
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.